Lifeward, a company specializing in technology to transform the lives of people with physical limitations or disabilities, announced that CEO Larry Jasinski will step down after 13 years of leading the company. He will continue to serve in his roles through Q2 2025 to help with a transition to a successor.

Lifeward’s board appointed a special committee to direct the search for its next CEO. It will consider external and internal candidates, in partnership with a nationally recognized firm.

“On behalf of the entire board of directors, we sincerely thank Larry for his unwavering dedication to the company and the people we serve,” said Joseph Turk, chairman of the Lifeward board of directors. “Larry has been a true champion in the pursuit of our mission to provide access to technology that changes lives of people with physical limitations or disabilities. We look forward to collaborating with him in the months ahead to ensure a smooth transition and wish him the very best.”

Jasinski has served as CEO and as a member of Lifeward’s board since February 2012. From 2005 until 2012, has was president and CEO of Soteira, a company engaged in development and commercialization of products used to treat individuals with vertebral compression fractures, which was acquired by Globus Medical in 2012.

From 2001 to 2005, Jasinski was president and CEO of Cortek, a company that developed next-gen treatments for degenerative disc disease, which was acquired by Alphatec in 2005. From 1985 until 2001, he served in multiple sales, research and development, and general management roles at Boston Scientific.

“I have been thrilled and honored to have led a remarkable team in creating a new industry that allowed the paralyzed community the ability to walk in everyday life,” said Jasinski. “I am grateful and thank all the individuals I worked with on this journey. The ReWalk team shepherded a concept to a working device, compiled extensive scientific data, secured regulatory approvals, established capacity to supply, and importantly—delivered patients access to technology through payment coverage by Medicare, German insurers and others. Simply put, we changed lives. We added the unique AlterG Anti-Gravity systems, Soft Exo-Suit technology with the ReStore stroke system and the MyoCycle FES system to the portfolio which form a solid foundation for Lifeward’s financial future.”

In June 2024, the company (formerly ReWalk Robotics) launched the AlterG NEO anti-gravity treadmill for physical rehabilitation and athletic training.

The company said it expects to report fiscal year 2024 revenue of about $25.7 million, matching its guidance range of $25-26 million. The company expects annual GAAP operating expenses to be about $33.4 million, including about $5.7 million in restructuring and impairment expenses.

Lifeward plans to provide its financial outlook for 2025 on its Q4 and full-year 2024 financial results conference call, to be scheduled during the week of March 10, 2025.